CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

mbg453

mAbexperimental

Clinical trial activity

17 trials · 5 clinical orgs · 0 marketing orgs

Phase 1
10
Phase 2
12
Phase 3
1
Phase 4
0

Earliest trial started Nov 23, 2015 (NCT02608268)

Timeline

2010s

  1. Jan 1, 2015

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2019

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2020

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • mbg453

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06664879Phase 1/Phase 2 (Phase 2)Feb 1, 2025Australasian Leukaemia and Lymphoma Group, University of Texas at Houston
NCT05367401Phase 1/Phase 2 (Phase 2)Dec 20, 2024Novartis
NCT05201066Phase 2Jan 2, 2023Novartis
NCT04823624Phase 2Sep 30, 2021Harvard University, Novartis
NCT04878432Phase 2Aug 31, 2021Novartis
NCT04810611Phase 1Jun 18, 2021Novartis
NCT04812548Phase 2May 31, 2021Novartis
NCT04623216Phase 1/Phase 2 (Phase 2)Apr 5, 2021Novartis
NCT04283526Phase 1Apr 30, 2020Novartis
NCT04266301Phase 3Apr 24, 2020Novartis
NCT04150029Phase 2Jan 20, 2020Novartis
NCT04097821Phase 1/Phase 2 (Phase 2)Sep 18, 2019Novartis
NCT03961971Phase 1Jun 30, 2019Johns Hopkins University, Novartis
NCT03946670Phase 2Jun 4, 2019Novartis
NCT03940352Phase 1May 10, 2019Novartis
NCT03066648Phase 1Jun 30, 2017Novartis
NCT02608268Phase 1/Phase 2 (Phase 2)Nov 23, 2015Novartis
Showing 17 of 17 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
NovartisFor profit161432015
Australasian Leukaemia and Lymphoma GroupAcademic/Hospital1012025
Harvard UniversityAcademic/Hospital1112021
Johns Hopkins UniversityAcademic/Hospital1112019
University of Texas at HoustonAcademic/Hospital1112025
5 organizations
Page 1 / 1